

9-27-02

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → 

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TECH CENTER  
600/2901615  
OCT 01 2002  
RECEIVEDTRANSMITTAL  
FORM

(to be used for all correspondence after initial filing)

		Application Number	09/897,801
		Filing Date	June 29, 2001
		First Named Inventor	Pinkerton
		Group Art Unit	1615
		Examiner Name	Azpuru
Total Number of Pages in This Submission	2	Attorney Docket Number	6794S-000019/US

## ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<b>Response to Restriction/ Election Requirement</b>
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		Remarks
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Donald R. Holland, Reg. No. 35,197
Signature	
Date	September 26, 2002

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name	Donald R. Holland, 35,197
Signature	
Date	September 26, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Express Mail No. EV196263785US



EV196263785US

PATENT CENTER 1600/2900  
Attorney Docket No. 6794S-00006

OCT 01 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Pinkerton :  
Serial No.: 09/897,801 :  
Filed: June 29, 2001 :  
For: ENHANCED PHARMACOKINETIC :  
PROFILE OF INTRADERMALLY :  
DELIVERED SUBSTANCES :

Art Unit: 1615

Examiner: C. Azpuru

13/Election  
KC

Commissioner for Patents  
Washington, D.C. 20231

Bef  
10-4-02


RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

This paper is submitted in response to Restriction/Election Requirement of September 24, 2002 and subsequent interview with Examiner on September 26, 2002. In the interview, restriction was required between Group 1, Claims 85-116 and 199-138 to a method of delivering intradermally and Group 2 Claims 117 and 118 to a device for delivering intradermally. Applicant elects Group 1 Claims 85-116 and 199-138 for further prosecution without traverse.

In addition, Applicant cancels Claim 23 without prejudice or disclaimer.

Should any questions arise, the Patent and Trademark Office is requested to contact the undersigned attorney.

Respectfully submitted,

  
Donald R. Holland Reg. No. 35197  
HARNESS, DICKEY & PIERCE, P.L.C.  
7700 Bonhomme, Suite 400  
St. Louis, Missouri 63105  
(314) 726-7500